Cargando…
Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
BACKGROUND: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received complementary and alternative medicine. Traditional Chinese herbal formula is widely used in Asia, and clinical stud...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896428/ https://www.ncbi.nlm.nih.gov/pubmed/35244043 http://dx.doi.org/10.1097/MD.0000000000028895 |
_version_ | 1784663161669943296 |
---|---|
author | Ji, Lijiang Zhao, Xiaoying Zhang, Yuyan Zhao, Ping Gong, Rui Li, Fang Huang, Hua |
author_facet | Ji, Lijiang Zhao, Xiaoying Zhang, Yuyan Zhao, Ping Gong, Rui Li, Fang Huang, Hua |
author_sort | Ji, Lijiang |
collection | PubMed |
description | BACKGROUND: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received complementary and alternative medicine. Traditional Chinese herbal formula is widely used in Asia, and clinical studies have also found that Chinese herbal formula could significantly improve abdominal pain and diarrhea. We plan to carry out a randomized, controlled, double blind, clinical studies to observe the clinical efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. METHODS: Four hundred sixty-four participants will be randomly assigned to the treatment group and control group. Patients in both groups would take medications and stimulations simultaneously. The outcomes of IBS symptom severity score, quality of life, psychological states, and recurrence rate will be recorded. Statistics will be analyzed with the SPSS 22.0. CONCLUSIONS: The findings of the study will identify the safety and efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. TRIAL REGISTRATION: OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/C8MHW. |
format | Online Article Text |
id | pubmed-8896428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-88964282022-03-07 Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial Ji, Lijiang Zhao, Xiaoying Zhang, Yuyan Zhao, Ping Gong, Rui Li, Fang Huang, Hua Medicine (Baltimore) 3800 BACKGROUND: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received complementary and alternative medicine. Traditional Chinese herbal formula is widely used in Asia, and clinical studies have also found that Chinese herbal formula could significantly improve abdominal pain and diarrhea. We plan to carry out a randomized, controlled, double blind, clinical studies to observe the clinical efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. METHODS: Four hundred sixty-four participants will be randomly assigned to the treatment group and control group. Patients in both groups would take medications and stimulations simultaneously. The outcomes of IBS symptom severity score, quality of life, psychological states, and recurrence rate will be recorded. Statistics will be analyzed with the SPSS 22.0. CONCLUSIONS: The findings of the study will identify the safety and efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. TRIAL REGISTRATION: OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/C8MHW. Lippincott Williams & Wilkins 2022-03-04 /pmc/articles/PMC8896428/ /pubmed/35244043 http://dx.doi.org/10.1097/MD.0000000000028895 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 3800 Ji, Lijiang Zhao, Xiaoying Zhang, Yuyan Zhao, Ping Gong, Rui Li, Fang Huang, Hua Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial |
title | Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial |
title_full | Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial |
title_fullStr | Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial |
title_full_unstemmed | Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial |
title_short | Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial |
title_sort | efficacy and safety of qinghua zhixie decoction against diarrhea-predominate irritable bowel syndrome: a protocol for a randomized controlled trial |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896428/ https://www.ncbi.nlm.nih.gov/pubmed/35244043 http://dx.doi.org/10.1097/MD.0000000000028895 |
work_keys_str_mv | AT jilijiang efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial AT zhaoxiaoying efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial AT zhangyuyan efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial AT zhaoping efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial AT gongrui efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial AT lifang efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial AT huanghua efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial |